Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.
- For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.
- However, just over 50% of them are on antiretroviral treatment compared to 76% of adults living with HIV on treatment today.
- Many LMICs have a high burden of mother-to-child transmission and the prevalence of HIV among children remains high.
- “By developing medicine formulations that meet the needs of children, and by improving palatability, through these partnership, we have the ability to potentially increase adherence rates in children.